SBIR/STTR Research Award
Novel agents for Alzheimer's Disease Therapy
Award amount
$100,000Program and phase
SBIR · Phase IAward year
2004Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Panacea Pharmaceuticals
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- QCMVY49NJQE4
- Solicitation number
- PHS2004-2
- Topic code
- Not reported
Research abstract
DESCRIPTION (provided by applicant): Alzheimer disease (AD) is the most common form of dementia and primarily affects older individuals. Currently approximately 4 million people in the United States (US) are affected with AD, and that number is expected t
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Development of Bacteriophage Therapy for Treatment of A. baumannii Infected Wounds
- A Novel Neuroprotective Approach for Ischemia
- A Novel Neuroprotective Approach for Ischemia
- Identification of Small Molecule Inhibitors of RSV Entry
- Development of DSB, a novel potent HIV inhibitor
Research funding history
14 SBIR/STTR records share this UEI (2000–2009). Reported award amounts total $5,832,992. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services, Department of Defense